##### 



Exhibit 10.36
 ***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2
 Research Cross-License Agreement
 This Research Cross-License Agreement Agreement Effective Date Micromet AG Micromet Enzon
Pharmaceuticals, Inc. Enzon Cambridge Antibody Technology Limited CAT Party Parties
 Whereas , Original Creative BioMolecules
License Agreement
 Whereas , Original Enzon License Agreement
 Whereas ,
 Whereas ,
 Whereas , Micromet/Enzon IP Marketing
Agreement
 Whereas ,




---



##### 



Now, Therefore ,
 1. Definitions
  1.1 Affiliate
 1.2 Antibody
 1.3 Antibody Product
 1.4 Antigen
 1.5 BiTE Product
 1.6 Business Day
 1.7 CAT Background Know-How Schedule VI
 1.8 CAT Collaboration Partner
 1.9 CAT Excluded Technology Schedule VIII
 1.10 CAT Field Limitations Schedule III
 2




---



##### 



1.11 CAT Licensed Patents Schedule II.
 1.12 CAT Phage Display Improvements provided however provided however
 1.13 CAT Research Contractor
 1.14 CAT Research Field
 1.15 Collaboration Agreement
 1.16 Consolidated Know-How Schedule VII
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 3




---



##### 



1.17 Consolidated Patent Portfolio Schedule I
 1.18 Consolidated Patent Portfolio Improvement provided however provided however
 1.19 Controlled Controls
 1.20 Diagnostic SCA Product Schedule VIII in vitro in vivo
 1.21 Enzon Collaboration Partner
 1.22 Enzon Research Contractor
 1.23 Enzon Research Field
 1.24 Enzon Supplemental Know-How
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 4




---



##### 



1.25 Enzon Supplemental Patents
 1.26 Excluded Field Schedule IV
 1.27 Excluded Target
 1.28 Existing Product Use Agreement Schedule XIII
 1.29 Exploit Exploitation
 1.30 Gatekeeping Criteria Schedule V
 1.31 Improvement
 1.32 Insolvency Event
 1.33 Know-How
 5




---



##### 



1.34 Library
 1.35 Maintenance Fee Term
 1.36 Major Market Country
 1.37 Micromet Collaboration Partner
 1.38 Micromet-Enzon Excluded Technology Schedule
VIII
 1.39 Micromet Research Contractor
 1.40 Micromet Research Field
 1.41 Micromet Supplemental Know-How
 1.42 Micromet Supplemental Patents
 1.43 Micromet/Enzon Collaboration Agreement
 1.44 Micromet/Enzon Cross-License Agreement
 1.45 [***] Agreement
 1.46 Nominated Target
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 6




---



##### 



1.47 Non-SCA Antibody Product Field provided however
 1.48 Non-SCA Antibody Products
 1.49 Notified Party
 1.50 Original Creative BioMolecules License Agreement
 1.51 Original Enzon License Agreement
 1.52 Patents
 1.53 Phage Display
 1.54 Platform Technology
 1.55 Primary Application
 1.56 Product License Agreement Schedules IX X.
 1.57 Requesting Party
 1.58 Ribosome Display in vitro
 1.59 SCA Product
 7




---



##### 



1.60 Single Chain Antibody SCA
 1.61 Target
 1.62 Term
 1.63 Therapeutic SCA Product
 1.64 Third Party
 1.65 Valid Claim
 2. Grant Of License
 2.1 Licenses Grant By Micromet.
 2.1.1 Research License To CAT.
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 8




---



##### 



2.1.2 No Restriction on CAT Exploitation Rights.
 2.1.3 Sublicenses by CAT.
 (a)
 (i)
 (ii)
 (iii)
 (iv)
 (b)
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 9




---



##### 



(c)
 2.1.4 Limitations; Reservation of Rights
 (a)
 (b)
 2.1.5 Expiration of CAT Field Limitations
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 10




---



##### 



2.1.6 Expansion of CAT Research Field.
 2.2 Research License Grant By CAT.
 2.2.1 To Micromet and Enzon.
 (a)
 (b)
 2.2.2 Sublicenses by Micromet
 (a)
 (i)
 (ii)
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 11




---



##### 



(iii)
 (b) Micromet Sublicense
Allowance provided however
 (c)
 2.2.3 Sublicenses by Enzon
 (a)
 (i)
 (ii)
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 12




---



##### 



(iii)
 (b) Enzon Sublicense
Allowance provided however
 (c)
 2.2.4 Expiration of Field Limitations on Micromet/Enzon.
 (a)
 (b) [***] License
Agreement
  2.2.5 Limitations; Reservation of Rights.
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 13




---



##### 



2.3 Know-How Transfer
 2.3.1
 2.3.2 Schedule VII Schedule VII
 3. Target Selection
 3.1 Identification and Allocation of Targets.
 3.1.1
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 14




---



##### 



3.1.2
 3.1.3
 3.1.4
  3.2 Notice and Selection Procedures.
 3.2.1 General. Request
Notice
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 15




---



##### 



Requesting Party Notified Party ®
 3.2.2 Requests by Micromet and/or Enzon to CAT.
 (a)
 (b)
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 16




---



##### 



(c)
 3.2.3 Requests by CAT to Micromet.
 (a)
 (b)
 (c)
 3.2.4 Excluded Targets Excluded Target
 (a)
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 17




---



##### 



(b) Status Change
 3.3 Product License Agreement.
 (a) Schedule IX
 (b) Schedule X;
 (c) Schedule X
 (d)
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 18




---



##### 



3.4 Records Retention.
 3.5 Financial Records, Audit Records
 3.6 Confidentiality. provided however provided further
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 19




---



##### 



3.7 Gatekeeping Disputes and Remedies.
 3.7.1
 3.7.2
 3.7.3
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 20




---



##### 



4. Payments; Annual Report
 4.1 Upfront License Fees.
 4.1.1 By CAT.
 4.1.2 By Micromet.
 4.1.3 By Enzon.
 4.1.4 Payment Offset
 4.1.5 Withholdings CAT Deduction Micromet/Enzon Deduction
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 21




---



##### 



4.2 License Maintenance Fees.
 4.2.1 By CAT.
 4.2.2 By Micromet.
 4.2.3 By Enzon.
 4.2.4 Payment Offset
 4.2.5 Withholdings CAT Fee Deduction Micromet/Enzon Fee Deduction
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 22




---



##### 



4.3 Payment.
 4.3.1 Payment Method.
 4.3.2 Currency Conversion for Payments.
 4.4 Annual Report
 4.5 Withholdings
 4.5.1 Paying Party Receiving Party Withholding Tax
 (a)
 (b)
 4.5.2
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 23




---



##### 



(a)
 (b)
 4.5.3
 4.5.4
 24




---



##### 



5. Filing, Prosecution, Maintenance of Patent Rights; Improvements
 5.1 Responsibilities
 5.2 Costs
 5.3 Notice
 5.3.1
 5.3.2
 5.4 Enforcement
 5.4.1 provided however
 5.4.2 provided however
 25




---



##### 



5.5 Patent Challenges by CAT
 5.5.1 provided however
 5.5.2
 5.6 Patent Challenges by Micromet or Enzon
 5.6.1 provided however
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 26




---



##### 



5.6.2
 5.7 Improvements
 5.7.1 To Own Technology
 (a)
 (b) Schedule I
 5.7.2 To Another Partys Technology.
 (a) Improvements by CAT
 (i) CAT Improvements provided however
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 27




---



##### 



(ii)
 (iii)
 (b) Improvements by Micromet or Enzon
 (i) E/M Improvements provided however
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 28




---



##### 



(ii)
 (iii)
 5.7.3 Further Assurances
 6. Representation and Warranties; Covenants
 6.1 Representations of Micromet provided however Schedule I Schedule XI Schedule XI
 29




---



##### 



Schedule XI
 6.2 Representations of CAT provided however Schedule II Schedules II XII Schedules II XII Schedule XII
 6.3 Reciprocal Representations and Warranties.
 6.4 Additional Covenants
 6.4.1 provided however
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 30




---



##### 



6.4.2 provided however
 6.4.3
 6.4.4
 6.5 DISCLAIMER OF WARRANTY.
 7. Confidentiality
 7.1 Definition. Disclosing Party Receiving Party
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 31




---



##### 



Confidential Information
 7.2 Exclusions.
 7.2.1
 (a)
 (b)
 (c)
 (d)
 (e)
 7.2.2
 7.3 Disclosure and Use Restriction.
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 32




---



##### 



7.4 Authorized Disclosure.
 7.4.1 provided however provided further
 7.4.2 provided however
 7.4.3 provided however
 7.4.4
 7.4.5
 7.4.6
 7.5 Use of Name.
 7.6 Press Releases.
 33




---



##### 



7.6.1 Proposed Disclosure
 7.6.2
 7.6.3
 7.7 Terms of Agreement to be Maintained in Confidence. provided however provided further
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 34




---



##### 



8. Term and Termination
 8.1 Term Term
 8.2 Termination for Material Breach.
 8.2.1
 8.2.2
 8.2.3
 8.3 Relinquishment of License Rights.
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 35




---



##### 



8.4 Consequences of Expiration and Termination.
 8.4.1 Material Breach.
 8.4.2 Survival of Certain Sublicenses. provided however
 8.4.3 Obligations Continue.
 8.4.4 Return of Confidential Information provided however
 8.5 Termination of Enzon Agreements or [ ] Agreement
 8.5.1 provided however
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 36




---



##### 



provided further
 8.5.2 provided however
 9. Indemnification and Insurance
 9.1 Indemnification by CAT. Losses Third Party Claim
 9.2 Indemnification by Micromet.
 9.3 Indemnification by Enzon.
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 37




---



##### 



9.4 Indemnification Procedure.
 9.4.1 Notice of Claim. Indemnitees Indemnitee Indemnified
Party Indemnifying Party Indemnification Claim Notice
 9.4.2 Prosecution of Claims.
 (a) Control of Defense.
 (i)
 (ii)
 38




---



##### 



(b) Right to Participate in Defense. provided however
 (c) Settlement.
 (d) Cooperation.
 9.5 Expenses.
 39




---



##### 



9.6 Insurance.
 10. Limitation of Liability
  11. Miscellaneous
 11.1 Assignment. provided however
 (a) provided further
 (i)
 (ii)
 (b)
  40




---



##### 



ab initio
 11.2 Severability.
 11.3 Governing Law; Dispute Resolution.
 11.3.1
 11.3.2 Dispute
 11.4 Notices.
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 41




---



##### 



42




---



##### 



11.5 Entire Agreement; Modifications.
 11.5.1 Entire Agreement
 (a)
 (b)
 (c)
 43




---



##### 



(d)
 11.5.2 Amendment
 11.6 Relationship of the Parties.
 11.7 Waiver.
 11.8 Counterparts.
 11.9 No Benefit to Third Parties.
 11.10 Further Assurance.
 44




---



##### 



11.11 English Language.
 11.12 Force Majeure
 11.13 Construction.
 [Remainder of this page is left blank intentionally. Signature page follows.]
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 45




---



##### 



In Witness Whereof,
 Micromet AGBy:
    
    /s/ Christian Itin

Christian Itin, Ph.DChief Business OfficerBy:
    
    /s/ G.K. Mirow

Name: G.K. MirowTitle: CFOEnzon Pharmaceuticals, Inc.By: 

Name:
    
    /s/ Arthur Higgins


Arthur HigginsTitle:
    
    Chairman & CEOCambridge Antibody Technology LimitedBy: 

Name:
    
    /s/ Diane Mellett


Diane MellettTitle:
    
    General Counsel
 Signature Page to the Research Cross-License Agreement




---



##### 



SCHEDULE I
 Consolidated Patent Portfolio
 Application
    
    Application
    
    
    
    
    
    
    
    Patent
    
    Date ofNumber
    
    Filing Date
    
    Country
    
    Title of Application
    
    Status
    
    Number
    
    Grant[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.




---



##### 



Application
    
    Application
    
    
    
    
    
    
    
    Patent
    
    Date ofNumber
    
    Filing Date
    
    Country
    
    Title of Application
    
    Status
    
    Number
    
    Grant[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 2




---



##### 



Application
    
    Application
    
    
    
    
    
    
    
    Patent
    
    Date ofNumber
    
    Filing Date
    
    Country
    
    Title of Application
    
    Status
    
    Number
    
    Grant[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 3




---



##### 



Application
    
    Application
    
    
    
    
    
    
    
    Patent
    
    Date ofNumber
    
    Filing Date
    
    Country
    
    Title of Application
    
    Status
    
    Number
    
    Grant[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 4




---



##### 



Targeted Multifunctional Proteins
 POLYPEPTIDE LINKERS FOR PRODUCTION OF BIOSYNTHETIC PROTEINS
 Patent /Country
    
    Application #
    
    Filed
    
    Publication #
    
    Inventors
    
    Title[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    
    
    [***]
    
    [***][***]
    
    
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 5




---



##### 



BIOSYNTHETIC ANTIBODY BINDING SITES/
 GENETICALLY ENGINEERED ANTIBODY ANALOGUES AND FUSION PROTEINS THEREOF
 Patent /Country
    
    Filed
    
    Application #
    
    Publication #
    
    Inventors
    
    Title[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 6




---



##### 



[***]
 Patent /Country
    
    Filed
    
    Application #
    
    Publication #
    
    Inventors
    
    Title[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
 
 **
    
    The license rights granted under this Agreement do not apply to claims relating to those
antibodies of specific sequences binding to [***], which antibodies are described or disclosed in
the above-described Patents, and such claims are excluded from the definition of the Consolidated
Patent Portfolio. [***]
 Patent /Country
    
    Filed
    
    Application #
    
    Publication #
    
    Inventors
    
    Title[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    
    
    [***]
    
    [***][***]
    
    [***]
    
    
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 7




---



##### 



[***]
 Patent /Country
    
    Filed
    
    Application #
    
    Publication #
    
    Inventors
    
    Title[***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 8




---



##### 



SCHEDULE II
 CAT Licensed Patents
 [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***][***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    [***]
    
    
    
    [***]
 
 *
    
    Patents in opposition proceedings.***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.




---



##### 



SCHEDULE III
 CAT Field Limitations
   
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.




---



##### 



SCHEDULE IV
 Excluded Field
 Excluded Field
  i.
    
    [***]ii.
    
    [***];iii.
    
    [***],iv.
    
    [***]v.
    
    [***]; and/orvi.
    
    [***],
 provided however
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.




---



##### 



SCHEDULE V
 Gatekeeping Criteria
      provided however
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.




---



##### 



SCHEDULE VI
 CAT Background Know-How
    
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.




---



##### 



SCHEDULE VII
 Consolidated Know-How
  
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.




---



##### 



SCHEDULE VIII
 Excluded Technology
 Micromet-Enzon Excluded Technology
 1.
    
    [***], meaning the technology claimed in the following Patents to which CAT has sole right,
title and interest: (a) [***]; (b) [***];2.
    
    [***], meaning solely those Antibodies which bind to and [***] and in which an Antibody
binding region is involved in said [***];3.
    
    Research Products, meaning those certain research products for which CAT has granted
certain exclusive rights to a Third Party under the [***] License Agreement, as may then be in
effect; and4.
    
    [***], meaning any Antibody [***] for the purpose of simultaneously detecting and/or
measuring [***] whereby that product:
 (a)
    
    contains or comprises:
 (i)
 (ii)
 (b)
    
    contains or comprises [***], and(c)
    
    is in a format where the [***], and(d)
    
    employs any type of [***], and(e)
    
    may be used [***](as appropriate), and(f)
    
    is not, by way of example, (i) any type [***] assay.
 CAT Excluded Technology
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 1




---



##### 



1.
    
    BiTE Products;2.
    
    Microarrays, as defined above in this Schedule; and3.
    
    any research and development activities employing any technology, other than Phage Display or
Ribosome Display, that changes the [***].
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 2




---



##### 



SCHEDULE IX
 Form of Product License Agreement
 (CAT as Licensor)
 (separately
filed)
 1




---



##### 



SCHEDULE X
 Form of Product License Agreement
 (Micromet as Licensor)
 (separately
filed)




---



##### 



SCHEDULE XI
 Currently Pending Conflict Cases within the Consolidated Patent Portfolio
 Micromet Owned
 Micromet-licensed (from Enzon)
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions. 1




---



##### 



SCHEDULE XII
 CAT Third Party Claims
  
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.




---



##### 



SCHEDULE XIII
 Existing Product Use Agreement
 Licensee
    
    Effective Date of Library License[***]
    
    [***][***]
    
    [***][***]
    
    [***][***]
    
    [***][***]
    
    [***][***]
    
    [***]
 
 ***
    
    Certain information on this page has been omitted and
filed separately with the Commission. Confidential treatment has been requested
with respect to the omitted portions.




---



##### 



Table Of Contents
 Page1.
    
    DEFINITIONS
    
    
    22.
    
    GRANT OF LICENSE
    
    
    82.1
    
    Licenses Grant By Micromet
    
    
    82.2
    
    Research License Grant By CAT
    
    
    102.3
    
    Know-How Transfer
    
    
    133.
    
    TARGET SELECTION
    
    
    143.1
    
    Identification and Allocation of Targets
    
    
    143.2
    
    Notice and Selection Procedures
    
    
    153.3
    
    Product License Agreement
    
    
    173.4
    
    Records Retention
    
    
    183.5
    
    Financial Records, Audit
    
    
    183.6
    
    Confidentiality
    
    
    183.7
    
    Gatekeeping Disputes and Remedies
    
    
    194.
    
    PAYMENTS; ANNUAL REPORT
    
    
    204.1
    
    Upfront License Fees
    
    
    204.2
    
    License Maintenance Fees
    
    
    214.3
    
    Payment
    
    
    224.4
    
    Annual Report
    
    
    224.5
    
    Withholdings
    
    
    225.
    
    FILING, PROSECUTION, MAINTENANCE OF PATENT RIGHTS; IMPROVEMENTS
    
    
    245.1
    
    Responsibilities
    
    
    245.2
    
    Costs
    
    
    245.3
    
    Notice
    
    
    245.4
    
    Enforcement
    
    
    245.5
    
    Patent Challenges by CAT
    
    
    255.6
    
    Patent Challenges by Micromet or Enzon
    
    
    255.7
    
    Improvements
    
    
    266.
    
    REPRESENTATION AND WARRANTIES; COVENANTS
    
    
    286.1
    
    Representations of Micromet
    
    
    28
 -i-




---



##### 



Table Of Contents
 Page6.2
    
    Representations of CAT
    
    
    296.3
    
    Reciprocal Representations and Warranties
    
    
    296.4
    
    Additional Covenants
    
    
    296.5
    
    DISCLAIMER OF WARRANTY
    
    
    307.
    
    CONFIDENTIALITY
    
    
    307.1
    
    Definition
    
    
    307.2
    
    Exclusions
    
    
    307.3
    
    Disclosure and Use Restriction
    
    
    317.4
    
    Authorized Disclosure
    
    
    317.5
    
    Use of Name
    
    
    327.6
    
    Press Releases
    
    
    327.7
    
    Terms of Agreement to be Maintained in Confidence
    
    
    338.
    
    TERM AND TERMINATION
    
    
    338.1
    
    Term
    
    
    338.2
    
    Termination for Material Breach
    
    
    338.3
    
    Relinquishment of License Rights
    
    
    348.4
    
    Consequences of Expiration and Termination
    
    
    348.5
    
    Termination of Enzon Agreements or [***] Agreement
    
    
    359.
    
    INDEMNIFICATION AND INSURANCE
    
    
    359.1
    
    Indemnification by CAT
    
    
    359.2
    
    Indemnification by Micromet
    
    
    369.3
    
    Indemnification by Enzon
    
    
    369.4
    
    Indemnification Procedure
    
    
    369.5
    
    Expenses
    
    
    389.6
    
    Insurance
    
    
    3810.
    
    LIMITATION OF LIABILITY
    
    
    3811.
    
    MISCELLANEOUS
    
    
    3811.1
    
    Assignment
    
    
    3811.2
    
    Severability
    
    
    3911.3
    
    Governing Law; Dispute Resolution
    
    
    39
 
 [***]
    
    Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions.
 -ii-




---



##### 



Table Of Contents
 Page11.4
    
    Notices
    
    
    4011.5
    
    Entire Agreement; Modifications
    
    
    4111.6
    
    Relationship of the Parties
    
    
    4211.7
    
    Waiver
    
    
    4211.8
    
    Counterparts
    
    
    4311.9
    
    No Benefit to Third Parties
    
    
    4311.10
    
    Further Assurance
    
    
    4311.11
    
    English Language
    
    
    4311.12
    
    Force Majeure
    
    
    4311.13
    
    Construction
    
    
    43
 -iii-




---



##### 



Exhibit 10.36
 ***Text Omitted and Filed Separately
Confidential Treatment Requested
Under 17 C.F.R. §§ 200.80(b)(4) and 240.24b-2
 AMENDMENT
TO
RESEARCH CROSS-LICENSE AGREEMENT
 This Amendment Amendment Micromet AG Micromet Enzon Pharmaceuticals, Inc. Enzon Cambridge Antibody Technology Limited CAT Party Parties
 Recitals
 A. Agreement
 B.
 Agreement
 Now, Therefore,
 1. Amendment to Section 1.14.
  2. Addition of Section 1.66.
 1.




---



##### 



PEC Patent ***
 3. Amendment to Sections 2.1. 3(b) , 2.2. 2(b) and 2.2. 3(b) .
 4. Amendment to Section 3.1.2.
 5. Amendment to Section 3.1.3.
 6. Amendment to Section 3.1.4.
 7. Amendment to Schedule I.
 8. Expiration of Excluded Field.
 9. Execution of Micromet or Enzon Product License Agreement.
 10. Execution of CAT Product License Agreement.
 11. Warranty and Indemnity.
 
 ***
    
    Certain information on this page has been
omitted and filed separately with the Commission. Confidential treatment has
been requested with respect to the omitted portions. 2.




---



##### 



12. Counterparts.
 13. Effectiveness.
 14. Continuing Effect.
 In Witness Whereof,
 Micromet AG
    
    Enzon Pharmaceuticals, Inc.By: /s/ Christian Itin
    
    By: /s/ Jeffrey H. BuchalterName: Christian Itin
    
    Name: Jeffrey H. BuchalterTitle: CEO
    
    Title: Chairman, President & CEO
 Cambridge Antibody Technology Lmited
    3.